NEW YORK, May 11, 2023 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (“Intelligent Bio Solutions,” “INBS” or the “Company”) (Nasdaq: INBS), a medical technology company delivering intelligent, ...
Intelligent Bio Solutions Inc. Reports 32.6% Surge in Gross Profit Amid Strategic Growth Initiatives
Intelligent Bio Solutions forecasts a 32.6% profit increase, driven by higher-margin cartridge sales and market expansion efforts. Intelligent Bio Solutions Inc. announced preliminary unaudited ...
NEW YORK, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“Intelligent Bio Solutions” or the “Company”), a medical technology company delivering intelligent, rapid, ...
Study designed to validate accuracy and real-world workplace performance of the Intelligent Fingerprinting Drug Screening System Company expects ...
Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced that its management ...
Intelligent Bio Solutions Inc. (INBS) announced the successful collection of new data that reinforces the performance of its Intelligent Fingerprinting Drug Screening System, which is crucial for its ...
View Intelligent Bio Solutions Inc. INBS stock quote prices, financial information, real-time forecasts, and company news from CNN.
NEW YORK, Feb. 21, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, ...
NEW YORK, Dec. 31, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing ...
On Thursday, Intelligent Bio Solutions Inc. (NASDAQ:INBS) announced preliminary fiscal second-quarter sales of approximately $0.61 million and six-month sales of roughly $1.48 million. Gross profit is ...
Intelligent Bio Solutions Inc. (NASDAQ:INBS) on Tuesday reported a third quarter 2025 loss of 44 cents per share, down from a loss of $1.43 a year ago. The noninvasive testing solutions provider ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results